5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Editors’ highlight picks from 2023 in EHJ Open

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          EHJ Open has just completed its Volume 3. Since three is the smallest number needed to create a pattern, the EHJ Open Section Editors have now started the process of shaping the journal for both authors and readers. Looking back at 2023, we see a pattern of increasing numbers of submissions and publications and also an escalating interest in the journal’s content. Figure 1 depicts the EHJ Open Volume 3 articles receiving the most attention in 2023, as measured by Altmetric Attention Score. In this editorial, the Section Editors have summarized some of the highlights, and also wanted to thank all Authors, Readers, Associate Editors, and Reviewers for sculpting Volume 3 and leading us into the 4th Volume. Figure 1 EHJ open publications from 2023 with highest altmetric attention score (data sourced from app.dimensions.ai, accessed 5 February 2024). 1–4 The section on Epidemiology & Prevention highlights that the distribution of potentially modifiable risk factors differs between high-income European countries (Belgium, France, and England), compared with South Africa and Uganda. The data on the risk score was prospectively collected, and the results reveal that compared to Europe which has more metabolic factors that contribute to the risk score, unhealthy dietary patterns, low physical activity, and a higher waist-hip ratio were more prevalent in South Africa. 5 Understanding the distribution is key for targeted interventions that can lower future cardiovascular disease for entire populations. 6 EHJ Open also has a specific section focusing on Cardiovascular Genetics with applicability to all subjects covered in the journal. In this context, Mendelian randomization (MR) adds a causal dimension to studies of cardiovascular risk. 7 As an example, MR analysis supported that short sleep duration increases peripheral artery disease. 8 The common paths of Vascular Medicine and Coronary Artery Disease were illustrated in EHJ Open by carotid and coronary atherosclerosis being associated with an estimated 24 h sodium excretion, 9 for which the underlying mechanisms remain to be fully explored. 10 The latter observations were linked to Hypertension , a subject also dedicated to an EHJ Open section. A study evaluating the prognostic impact of the absence vs. presence of hypertension-mediated organ damage (left ventricular hypertrophy, carotid plaques, and chronic kidney disease) showed that ageing, the magnitude of insulin resistance, antiplatelet therapy, and multiple sites with hypertension-mediated organ damage were associated with future cardiovascular events, whereas a negative association was found with renin–angiotensin system blocker drugs. 11 This study extends previous observations 12 and suggests how cardiovascular risk assessment can be improved in clinical practice by using readily available information. Environmental pollution may alter dietary exposome towards increased cardiovascular risk. 13 As an example, serum arsenic levels may provide a concentration-dependent link between fish intake and hypertension, for which a causal mechanism was shown in a mouse model. 14 Further Translational Basic Science from Volume 3 reinforced the important role of lipids, showing that very low-density lipoprotein can alter intracellular fatty acid ratio of arachidonic to docosahexaenoic acid (AA/DHA) in C4+ T cells, which promoted Th1-skewing and atherosclerosis. 15 Interestingly, a recent large meta-analysis indicated that plant-based diets lower atherogenic lipoproteins and cardiovascular risk. 16 How diet and its fatty acid content influence T-cell-mediated inflammation and atherosclerotic burden warrants further investigation. Cardiac amyloidosis (CA), a progressive infiltrative disease caused by the cardiac deposition of amyloid fibrils, 17 has received attention in EHJ Open 2023 across sections. In Valvular Heart Disease , EHJ Open presented a State-of-the-Art review on the association of CA with aortic stenosis, from pathophysiology to treatment. 18 Furthermore, in Arrhythmia & Electrophysiology, Ullah et al. used nationwide health data to conclude that atrial fibrillation ablation was associated with significantly higher net adverse clinical events in patients with CA, 19 albeit atrial fibrillation catheter ablation remains effective to maintain sinus rhythm in patients with CA. 20 Finally, novel findings on Vascular & Cardiac Imaging of CA include a suggested novel echocardiographic risk score 21 and CA prognostic prediction by cardiac magnetic resonance imaging (cMRI). 22 The latter section also includes an article showing that low preoperative left atrial reservoir strain was a risk factor for after coronary artery bypass grafting (CABG) ischaemic stroke in 542 patients over a median follow-up of almost 4 years, independently of the occurrence of postoperative atrial fibrillation (POAF). 23 This work considerably refines the insights from Butt et al. 24 about the prognostic value of POAF in CABG patients regarding stroke events. POAF complicates 20–40% of cardiac surgical procedures. Underlying mechanisms are incompletely defined but include intraoperative and postoperative phenomena, such as inflammation, sympathetic activation, and cardiac ischaemia. 25 The EHJ Open section on Interventional Cardiology & Cardiac Surgery introduced that the arterial stiffness measure cardio ankle vascular index (CAVI) predicted POAF after surgical aortic valve stenosis replacement. 26 Results stemming from a retrospective cohort of 4659 patients who underwent transcatheter aortic valve implantation (TAVI) at two high-volume, early adopter centres, in the United States and in Germany, the main finding was a correlation between right ventricular (RV) stimulation rates and higher risk for all-cause mortality and heart failure-related hospitalizations at 1-year. 27 These findings were independent of previously implanted pacemaker, suggesting a direct association between non-physiological ventricular activation and adverse clinical outcomes. The study addressed one of highly debated topics during this past year, namely the clinical impact of pacemaker stimulation in TAVI recipients, adding evidence to extend and confirm similar preliminary findings from a single-centre study, also confirming the previous evidence about the role played by pre-existing right bundle branch block as independent predictor of the need for pacemaker stimulation after TAVI, transposing the association to the rate of RV stimulation. 28,29 Along the same line, they also confirm that implantation depth and post-dilatation of the aortic prosthesis independently predict the need for pacing, supporting the findings from a multidisciplinary research group from Ghent University. In fact, using advanced in-silico modelling, they provided a mechanistic explanation of the impact exerted by the contact pressure generated with self-expandable aortic prostheses and the development of new conduction abnormalities. 30 Cardio-oncology represents one of the Special Populations in a dedicated EHJ Open section, in which a prospective cohort study of 47 women with newly diagnosed stage 1–3 human epidermal growth factor receptor (HER) 2-positive breast cancer showed that HER2-directed therapy alone had no major effect on vascular reactivity and vascular biomarkers, but the addition of anthracycline/cyclophosphamide can lead to a deterioration in vascular and cardiac function. 31 These results fill a part of the gap in knowledge of the emerging problem of vascular effects of cancer therapies. 32 Pelosi et al. showed that adults with Adult Congenital Heart Disease (ACHD), especially those with moderate/severe ACHD have an optimistic view of their life-expectancy and clearly more optimistic than their cardiologist. 33 In addition, growing attention is warranted for discussions on end-of-life and patients’ life-expectancy to improve care. 34 Takotsubo syndrome (TTS) can be complicated by cardiogenic shock (CS), which represents one of the leading causes of mortality in TTS. 35 In a multi-centre observational registry, the use of Heart Failure treatment with intra-aortic balloon counterpulsation was however not associated with lower mortality rates at short- and long-term follow-up in patients with TTS and CS. 36 These editors’ highlight picks from 2023 illustrate the breadth of topics covered by EHJ Open. Stay tuned to #EHJOpen for more content. Among the new year’s resolutions, novel research results should soon become available to further promote open and interactive cardiology for an accelerated and global sharing of cardiovascular science.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          One-year cardiovascular event rates in outpatients with atherothrombosis.

          Few data document current cardiovascular (CV) event rates in stable patients with atherothrombosis in a community setting. Differential event rates for patients with documented coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD) or those at risk of these diseases have not been previously evaluated in a single international cohort. To establish contemporary, international, 1-year CV event rates in outpatients with established arterial disease or with multiple risk factors for atherothrombosis. The Reduction of Atherothrombosis for Continued Health (REACH) Registry is an international, prospective cohort of 68 236 patients with either established atherosclerotic arterial disease (CAD, PAD, CVD; n = 55 814) or at least 3 risk factors for atherothrombosis (n = 12 422), who were enrolled from 5587 physician practices in 44 countries in 2003-2004. Rates of CV death, myocardial infarction (MI), and stroke. As of July 2006, 1-year outcomes were available for 95.22% (n = 64 977) of participants. Cardiovascular death, MI, or stroke rates were 4.24% overall: 4.69% for those with established atherosclerotic arterial disease vs 2.15% for patients with multiple risk factors only. Among patients with established disease, CV death, MI, or stroke rates were 4.52% for patients with CAD, 6.47% for patients with CVD, and 5.35% for patients with PAD. The incidences of the end point of CV death, MI, or stroke or of hospitalization for atherothrombotic event(s) were 15.20% for CAD, 14.53% for CVD, and 21.14% for PAD patients with established disease. These event rates increased with the number of symptomatic arterial disease locations, ranging from 5.31% for patients with risk factors only to 12.58% for patients with 1, 21.14% for patients with 2, and 26.27% for patients with 3 symptomatic arterial disease locations (P<.001 for trend). In this large, contemporary, international study, outpatients with established atherosclerotic arterial disease, or at risk of atherothrombosis, experienced relatively high annual CV event rates. Multiple disease locations increased the 1-year risk of CV events.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

            Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Postoperative atrial fibrillation: mechanisms, manifestations and management

              Postoperative atrial fibrillation (POAF) complicates 20-40% of cardiac surgical procedures and 10-20% of non-cardiac thoracic operations. Typical features include onset at 2-4 days postoperatively, episodes that are often fleeting and a self-limited time course. Associated adverse consequences of POAF include haemodynamic instability, increased risk of stroke, lengthened hospital and intensive care unit stays and greater costs. Underlying mechanisms are incompletely defined but include intraoperative and postoperative phenomena, such as inflammation, sympathetic activation and cardiac ischaemia, that combine to trigger atrial fibrillation, often in the presence of pre-existing factors, making the atria vulnerable to atrial fibrillation induction and maintenance. A better understanding of the underlying mechanisms might enable the identification of new therapeutic targets. POAF can be prevented by targeting autonomic alterations and inflammation. β-Blocker prophylaxis is the best-established preventive therapy and should be started or continued before cardiac surgery, unless contraindicated. When POAF occurs, rate control usually suffices, and routine rhythm control is unnecessary; rhythm control should be reserved for patients who develop haemodynamic instability or show other indications that rate control alone will be insufficient. In this Review, we summarize the epidemiological and clinical features of POAF, the available pathophysiological evidence from clinical and experimental investigations, the results of prophylactic and therapeutic approaches and the consensus recommendations of various national and international societies.
                Bookmark

                Author and article information

                Contributors
                Journal
                Eur Heart J Open
                Eur Heart J Open
                ehjopen
                European Heart Journal Open
                Oxford University Press (US )
                2752-4191
                January 2024
                22 February 2024
                22 February 2024
                : 4
                : 1
                : oeae008
                Affiliations
                Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital , 17176 Stockholm, Sweden
                Department of Medicine Solna, Karolinska Institutet , 17176 Stockholm, Sweden
                Nancy University Hospital, University of Lorraine and INSERM U1116 , 54505 Vandoeuvre les Nancy Cedex, France
                Department of Preventive Cardiology and Lipidology, Medical University of Lodz and Polish Mother’s Memorial Hospital Research Institute , Lodz, Poland
                Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital , 17176 Stockholm, Sweden
                Department of Medicine Solna, Karolinska Institutet , 17176 Stockholm, Sweden
                Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro , Italy
                Divisions of Clinical Physiology and Cardiology, Uppsala University Clinic, and the Department of Medical Sciences, Uppsala University , Uppsala, Sweden
                Department of Cardiology, Danderyd University Hospital , Stockholm, Sweden
                Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm, Sweden
                Department of Medicine Solna, Karolinska Institutet , 17176 Stockholm, Sweden
                Department of Molecular Medicine, University of Southern Denmark , Odense, Denmark
                University of Liège Hospital, GIGA Cardiovascular Sciences, Centre Hospitalier Universitaire Sart Tilman , Liège, Belgium
                Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet , Stockholm, Sweden
                Department of Surgical Sciences, Uppsala University , Uppsala, Sweden
                Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital , 17176 Stockholm, Sweden
                Department of Medicine Solna, Karolinska Institutet , 17176 Stockholm, Sweden
                Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital , 17176 Stockholm, Sweden
                Department of Medicine Solna, Karolinska Institutet , 17176 Stockholm, Sweden
                Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital , 17176 Stockholm, Sweden
                Department of Medicine Solna, Karolinska Institutet , 17176 Stockholm, Sweden
                Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital , 17176 Stockholm, Sweden
                Department of Medicine Huddinge, Karolinska Institutet , Stockholm, Sweden
                Nancy University Hospital, University of Lorraine and INSERM U1116 , 54505 Vandoeuvre les Nancy Cedex, France
                Author notes
                Corresponding author. Tel: +46812370000, Email: magnus.back@ 123456ki.se

                Conflict of interest: none declared.

                Author information
                https://orcid.org/0000-0003-0853-5141
                https://orcid.org/0000-0002-4966-1315
                https://orcid.org/0000-0001-5388-942X
                https://orcid.org/0000-0002-0994-8135
                https://orcid.org/0000-0003-4846-6793
                Article
                oeae008
                10.1093/ehjopen/oeae008
                10882979
                38390349
                0be3c6e4-c26f-4cd9-8587-f49876f8cce8
                © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 07 February 2024
                : 08 February 2024
                : 22 February 2024
                Page count
                Pages: 4
                Categories
                Editorial
                Miscellaneous
                AcademicSubjects/MED00200

                Comments

                Comment on this article